Investigational drug · Phase 3
VX-147
Also called: Inaxaplin, IXP
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Proteinuric Kidney Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "VX-147"
First trial start
2022
Mar 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VX-147", any sponsor or status.
Conditions studied
As listed on its trial records.
- Proteinuric Kidney Disease
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "VX-147" as an intervention, largest first.
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseasePivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05312879 · 522 participants · Start Mar 30, 2022 · Primary completion Jun 2, 2028
Drug: VX-147; Placebo · For: Proteinuric Kidney Disease
Sites: Alabaster, Alabama; Birmingham, Alabama; Fairhope, Alabama · 314 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06794996 · 42 participants · Start Feb 4, 2025 · Primary completion Jul 20, 2026
Drug: Inaxaplin · For: Proteinuric Kidney Disease
Sites: Huntsville, Alabama; Hollywood, Florida; Lauderdale Lakes, Florida · 35 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06529796 · 36 participants · Start Aug 2, 2024 · Primary completion Dec 20, 2024
Drug: IXP · For: Focal Segmental Glomerulosclerosis (FSGS)
Sites: Miami, Florida; St. Petersburg, Florida; San Antonio, Texas
- A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147Completed
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05955872 · 21 participants · Start Jul 19, 2023 · Primary completion Sep 2, 2023
Drug: VX-147 · For: Focal Segmental Glomerulosclerosis (FSGS)
Sites: Salt Lake City, Utah
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04340362 · 16 participants · Start Jun 8, 2020 · Primary completion Nov 11, 2021
Drug: VX-147 · For: Glomerulosclerosis, Focal Segmental
Sites: Birmingham, Alabama; San Diego, California; Washington D.C., District of Columbia · 44 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05865171 · 16 participants · Start Jun 12, 2023 · Primary completion Jun 12, 2024
Drug: IXP · For: Renal Impairment
Sites: Ocala, Florida; Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Expression of Apolipoprotein L1 Risk Variants at the Plasma Membrane and Haplotype-Dependent Cytotoxicity.
Adebayo OC, Dallali I, Kerselaers S, et al. · J Am Soc Nephrol 2026
- APOL1 kidney disease: a critical narrative review of molecular mechanisms, clinical heterogeneity, and the emerging therapeutic landscape.
Dogra N, Baranwal M, Ahmad S, et al. · Int Urol Nephrol 2026
- Design and optimization of isoxsuprine-loaded novasomes for the attenuation of coronary artery disease in rats.
Fouad AG, Belal A, Bukhari SM, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Polyacrylonitrile/polypyrrole nanofiber-filled packed-fiber solid-phase extraction coupled with HPLC-FLD for matrix-interference-resistant determination of urinary pteridines and its application in autism spectrum disorder research.
Liu Y, Yan Y, Wu C, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2026
- The urinary Isoxanthopterin/pterin Ratio Reflects Mild Fasting Hyperglycemia in Obese Patients with Type 2 Diabetes Mellitus: An Exploratory Cross-sectional Study.
Chinen R, Shirakura T, Hashimoto R, et al. · Intern Med 2026
- Effects of intercropping different quinoa cultivars on peanut rhizosphere microorganisms and yield in saline-alkali soil.
Liang X, Fu R, Chen C, et al. · Front Microbiol 2025
Also in development for Proteinuric Kidney Disease
- MZE829Phase 21 trial
Maze Therapeutics · Proteinuric Kidney Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.